NM_006158.5(NEFL):c.23C>T (p.Pro8Leu)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Inborn genetic diseases
β
β
ββ2025β Residue 8
NM_006158.5(NEFL):c.293A>G (p.Asn98Ser)Pathogenic
Charcot-Marie-Tooth disease type 1F|not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease, dominant intermediate G|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 1F;Charcot-Marie-Tooth disease type 2E;Charcot-Marie-Tooth disease, dominant intermediate G|Developmental disorder;Sensorineural hearing loss disorder|NEFL-related disorder
β
β
ββ2025β Residue 98
NM_006158.5(NEFL):c.1186G>A (p.Glu396Lys)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease, dominant intermediate G|Charcot-Marie-Tooth disease|Charcot-Marie-Tooth disease type 1F
β
β
ββ2025β Residue 396
NM_006158.5(NEFL):c.1150A>T (p.Ile384Phe)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided
β
β
ββ2025β Residue 384
NM_006158.5(NEFL):c.556G>T (p.Glu186Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided
β
β
ββ2025β Residue 186
NM_006158.5(NEFL):c.268G>A (p.Glu90Lys)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β
β
ββ2025β Residue 90
NM_006158.5(NEFL):c.1195C>T (p.Arg399Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 1F|Charcot-Marie-Tooth disease type 2E
β
β
ββ2024β Residue 399
NM_006158.5(NEFL):c.1261C>T (p.Arg421Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease|not provided
β
β
ββ2024β Residue 421
NM_006158.5(NEFL):c.292A>C (p.Asn98His)Likely pathogenic
not provided|Charcot-Marie-Tooth disease, dominant intermediate G
β
β
ββ2024β Residue 98
NM_006158.5(NEFL):c.23C>G (p.Pro8Arg)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E|Charcot-Marie-Tooth disease|Inborn genetic diseases
β
β
ββ2024β Residue 8
NM_006158.5(NEFL):c.54C>G (p.Tyr18Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
β
ββ2023β Residue 18
NM_006158.5(NEFL):c.64C>T (p.Pro22Ser)Pathogenic
Charcot-Marie-Tooth disease type 2E|not provided|Charcot-Marie-Tooth disease type 1C|Peripheral neuropathy;Pes cavus;Distal lower limb muscle weakness|Peripheral neuropathy;Decreased nerve conduction velocity;Peripheral demyelination;Hand muscle atrophy;Distal muscle weakness|Charcot-Marie-Tooth disease type 1F|Inborn genetic diseases
β
β
ββ2022β Residue 22
NM_006158.5(NEFL):c.417C>G (p.Tyr139Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β
β
ββ2022β Residue 139
NM_006158.5(NEFL):c.18C>G (p.Tyr6Ter)Pathogenic
Charcot-Marie-Tooth disease type 1F
β
β
ββ2022β Residue 6
NM_006158.5(NEFL):c.865G>T (p.Glu289Ter)Pathogenic
not provided|Charcot-Marie-Tooth disease type 2E
β
β
ββ2022β Residue 289
NM_006158.5(NEFL):c.171C>G (p.Tyr57Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
βββ2024β Residue 57
NM_006158.5(NEFL):c.417C>A (p.Tyr139Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
βββ2024β Residue 139
NM_006158.5(NEFL):c.223C>T (p.Gln75Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
βββ2024β Residue 75
NM_006158.5(NEFL):c.720C>G (p.Tyr240Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
βββ2024β Residue 240
NM_006158.5(NEFL):c.1099C>T (p.Arg367Ter)Pathogenic
Charcot-Marie-Tooth disease type 2E
β
βββ2024β Residue 367